Key Highlights
- Strategic Entry into the Oral Nicotine Market
Nasdaq-listed Ispire (ISPR) announces the formation of a joint venture with Jincheng Pharmaceutical to jointly manufacture and market nicotine pouch products. This collaboration marks an expansion of the company’s business operations, extending beyond electronic vaping hardware into the realm of oral nicotine products.
- Introduction of Pharmaceutical-Grade Manufacturing Capabilities
Under the agreement. Jincheng Pharmaceutical will provide manufacturing equipment, technical expertise, and raw materials for nicotine pouches, thereby accelerating the establishment of production capacity.
- Integration of Global Channels and Compliance Expertise
The joint venture will leverage Ispire’s capabilities in global regulatory compliance and international distribution networks to cultivate new revenue streams.
- Strategic Extension of a Diversified Smokeless Product Portfolio
This strategic initiative constitutes a pivotal component of Ispire’s multi-category, harm-reduction nicotine strategy.
Ispire Officially Enters the Fast-Growing Oral Nicotine Market
May 13, 2026. According to an announcement released by Ispire Technology via PR Newswire. Ispire Technology (NASDAQ: ISPR) announced on May 12 the formation of a strategic joint venture with Shandong Jincheng Pharmaceutical Group Co., Ltd. (SZSE: 300233) to jointly manufacture and commercialize nicotine pouch products.
Ispire stated that this collaboration signifies the company’s formal entry into the rapidly expanding oral nicotine market and further broadens its portfolio of novel nicotine products beyond its core electronic vaping hardware business.
The company noted that this partnership will combine Jincheng Pharmaceutical’s pharmaceutical-grade manufacturing capabilities with Ispire’s expertise in global regulatory affairs, precision dosage control, and international distribution.
Global Nicotine Pouch Market Expected to See Rapid Growth
Citing data from Grand View Research. Ispire noted that the global nicotine pouch market is projected to reach a size of approximately $7 billion in 2025. Furthermore, the market is expected to sustain an annual growth rate of nearly 25% through 2033, with its total market size projected to exceed $40 billion.
Michael Wang, Co-CEO of Ispire, stated:
- “Nicotine pouches represent a significant growth category globally; this collaboration enables us to rapidly enter the market by leveraging our existing operational capabilities and pharmaceutical-grade manufacturing expertise.”
He noted that, by combining this initiative with Ispire’s existing global distribution and regulatory infrastructure. The company aims to establish new revenue streams and advance its broader global nicotine platform strategy.
Jincheng Pharmaceutical to Support Production and Commercialization
Under the agreement. Jincheng Pharmaceutical will provide the joint venture with manufacturing equipment, technical capabilities, and materials related to nicotine pouches to support rapid mass production and commercialization.
Ispire, in turn, will contribute expertise in precise dosage control, global regulatory compliance, and international market distribution capabilities.
Jiaquan Li, Chairman and President of Jincheng Pharmaceutical, commented:
- “Ispire’s mature manufacturing capabilities and global regulatory experience will help us accelerate the commercialization process.”
According to public records. Jincheng Pharmaceutical employs approximately 3,800 people across more than 30 affiliated enterprises, with operations spanning the R&D and production of pharmaceutical intermediates. Active Pharmaceutical Ingredients (APIs), finished dosage forms, and health products.
Ispire Expands Its Diversified Nicotine Product Strategy
Ispire stated that initial production will be advanced through existing commercial partnerships, and the company plans to further expand its business opportunities within the oral nicotine sector.
The company noted that this expansion is part of its ongoing strategy to diversify its portfolio of harm-reduction nicotine products.
Ispire currently focuses primarily on the R&D, design, sales, and distribution of vapes and cannabis vaporization products, holding over 400 patents globally.
Its Aspire-branded vapes are currently sold primarily in markets outside of the United States, China, and Russia; the company also provides ODM services to vape brands and retailers worldwide.
Follow us to get more updates: @zumo.official
